EGFR and non-small cell lung carcinoma: Up to 47.9% of Asian NSCLC patients harbour EGFR mutation.2, 3 Fusion of the Echinoderm microtubule‐associated protein like‐4 (EML4) and anaplastic lymphoma kinase (ALK) represent another distinct mechanism of driver mutation in NSCLC, accounting for about 4%‐8.1% patients.4, 5 Although chemotherapy remains the main treatment of advanced NSCLC, small molecular tyrosine kinase inhibitors (TKIs) were recommended as the first‐line treatment of advanced NSCLC with druggable driver mutations.